<DOC>
	<DOCNO>NCT00319761</DOCNO>
	<brief_summary>Immunoglobulin A ( IgA ) nephropathy common type primary glomerulonephritis world . A wealth literature suggest vitamin D analog profound effect immune system function glomerular mesangial cell proliferation . Calcitriol , active form vitamin D , commonly use treatment secondary hyperparathyroidism patient advance chronic kidney disease . Therefore , investigator plan conduct open-label single-arm study evaluate safety efficacy calcitriol treatment IgA nephropathy . Ten patient biopsy-proven IgA nephropathy persistent proteinuria despite conventional therapy recruit . They treat calcitriol 12 week . Proteinuria , renal function , serum urinary inflammatory marker monitor . This study explore potential anti-proteinuric anti-inflammatory effect calcitriol treatment IgA nephropathy , major cause dialysis-dependent renal failure .</brief_summary>
	<brief_title>Calcitriol Treatment Immunoglobulin A ( IgA ) Nephropathy</brief_title>
	<detailed_description>This open-label single arm study . We plan recruit 10 patient biopsy-proven IgA nephropathy recruit . Treatment regimen dosage adjustment At week 0 , patient receive calcitriol ( oral capsule ) fix dose 0.5 mcg twice weekly . If adverse effect correct serum calcium remain &lt; 2.55 mmol/l , dose calcitriol maintain 12 week . If correct serum calcium 2.55 2.62 mmol/l , dose calcitriol reduce 0.25 mcg twice weekly . Serum calcium rechecked 2 week ( frequently indicate ) . If correct serum calcium remain &lt; 2.55 mmol/l , dose calcitriol maintain rest study period . If correct serum calcium remain &gt; 2.62 mmol/l two consecutive measurement despite reduce dose calcitriol , study medication stop subject discontinue study . If correct serum calcium &gt; 2.75 mmol/l time , hold calcitriol one week repeat laboratory test calcium . If subject 's next serum calcium &lt; 2.62 mmol/l , calcitriol may restart 0.25 mcg twice weekly . If next serum calcium level &gt; 2.62 mmol/l , subject discontinue study . Concomitant therapy Prior enrollment , patient stable receive ACE inhibitor angiotensin receptor blocker . Anti-hypertensive therapy titrate throughout study period maintain blood pressure 130 / 80 mmHg . Visit schedule Follow visit take place accord follow schedule : - week -4 ( screen ) - week 0 ( start calcitriol ) , 2 , 4 , 6 , 8 , 12 ( stop calcitriol ) 16 During every visit , follow parameter measure : body weight , blood pressure , pulse , adverse effect treatment , complete blood picture , differential white cell count , renal function test , liver enzyme , serum calcium , phosphate , early morning urine collection protein-to-creatinine ratio . Renal function determine estimate glomerular filtration rate ( GFR ) accord standardize formula [ 20 ] . Serum fast glucose lipid profile measure 0 12 week . In order examine anti-proliferative anti-inflammatory action calcitriol , serum level C-reactive protein ( CRP ) , interleukin-6 ( IL-6 ) transform growth factor-beta ( TGF ) , urinary level TGF , hepatocyte growth factor ( HGF ) , monocyte chemoattractant protein-1 ( MCP-1 ) thrombospondin-1 ( TSP-1 ) measure 0 , 4 , 12 16 week ELISA . The panel cytokine choose document relevance IgA nephropathy progressive renal failure [ 16,19,21-27 ] . End point Primary end point study change degree proteinuria . Secondary end point include change renal function serum inflammatory marker . Adverse event Information every adverse event collect record . An adverse event undesirable symptom medical condition occur start study medication , whether consider drug-related . Patient withdrawal The patient withdrawn study : - death - double baseline serum creatinine level - pregnancy - hypercalcemia ( serum calcium &gt; 2.62 mmol/L two consecutive measurement ) - intolerable adverse event - significant non-compliance protocol - desire patient withdraw study All female patient advise take effective contraceptive measure study period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin A</mesh_term>
	<criteria>age 1865 year biopsyconfirmed IgA nephropathy proteinuria &gt; 1 g/day ( proteinuria &gt; 1 g/gCr ) 2 consecutive sample within 12 week despite ACE inhibitor angiotensin receptor blocker treatment ( ramipril 5 mg daily , lisinopril 10 mg daily , valsartan 80 mg daily ) least 3 month estimate glomerular filtration rate 15 60 ml/min/1.73m2 correct serum calcium level M 2.45 mmol/l willingness give write consent comply study protocol Pregnancy , lactate childbearing potential without effective method birth control Severe gastrointestinal disorder interfere ability receive absorb oral medication History malignancy , include leukemia lymphoma within past 2 year Systemic infection require therapy study entry Any severe coexisting disease , limited , chronic liver disease , myocardial infarction , cerebrovascular accident , malignant hypertension History drug alcohol abuse within past 2 year Participation previous trial vitamin D analogue Patients receive treatment vitamin D and/or analogue medical reason within past 3 month Patients receive treatment corticosteroid On investigational drug within last 30 day History psychological illness condition interfere patient 's ability understand requirement study History noncompliance Known history sensitivity allergy vitamin D analog</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>glomerulonephritis</keyword>
	<keyword>proteinuria</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>